Deborah Dunsire - Sep 9, 2021 Form 4 Insider Report for Syros Pharmaceuticals, Inc. (SYRS)

Role
Director
Signature
/s/ Gerald E. Quirk, as attorney-in-fact
Stock symbol
SYRS
Transactions as of
Sep 9, 2021
Transactions value $
$0
Form type
4
Date filed
9/10/2021, 05:30 PM
Previous filing
Jul 23, 2021
Next filing
Jun 2, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SYRS Stock Option (right to buy) Award $0 +35K $0.00 35K Sep 9, 2021 Common Stock 35K $5.28 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option becomes exercisable as to 16.66% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the third anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date.